INDIA GLYCOLS LTD

The investor presentation for India Glycols Limited's subsidiary, Ennature Biopharma, outlines its strategic positioning in the global nutraceutical and botanical ingredients market. The document highlights Ennature's three core businesses: Plant-based APIs, Biopolymers (Guar), and Branded Nutraceuticals. The API segment, a mature and cash-generative business, serves global and domestic pharmaceutical customers with products like Thiocolchicoside and Colchicine, supported by EU-GMP and US-FDA certifications. The Biopolymer segment, with 69% export revenues, targets diverse end-markets including food, personal care, and textiles, focusing on dietary fibre applications and value-added derivatives. The Branded Nutraceuticals segment, positioned as the future growth engine, includes products like Aspargize and Xanthogreen, with strategies to expand into regulated markets and build clinical validation. Ennature emphasizes its science-led approach, global quality certifications, and patented technologies to differentiate its offerings. Financial highlights for FY26 show revenue of INR 246 crore and an EBITDA margin of 11.9%. Management aims to scale its branded portfolio, expand geographically, and deepen customer relationships across key markets.

The document emphasizes growth opportunities, strategic expansion, and competitive differentiation through science and innovation.